Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap - LARVOL DELTA

Real-world comparison of treatments with antibodies targeting the CGRP pathway or botulinum toxin type A for resistant migraine. (PubMed, Rev Neurol (Paris)) - "Anti-CGRP mAbs demonstrated superior efficacy compared to BTX-A in resistant migraine patients."

Journal • Real-world evidence • CNS Disorders • Migraine • Pain

Constraint-induced Movement Therapy Versus Task-oriented Training On Upper Extremity Function Post-Botox Injection in Stroke Patients (clinicaltrials.gov) - P=N/A | N=51 | Completed | Sponsor: Cairo University | Not yet recruiting ➔ Completed

Trial completion • Cardiovascular

Intradetrusor OnabotulinumtoxinA Safety and Efficacy in Patients 80 Years and Older: A Retrospective Cohort Study. (PubMed, Int Urogynecol J) - "Women ≥ 80 years old were most likely to discontinue BTX-A but discontinuing for ineffectiveness was the same regardless of age. Women > 65 are more likely to experience UTI after BTX-A; however, AEs do not significantly increase in women ≥ 80 years old, making BTX-A a good option in elderly patients."

Journal • Retrospective data • Overactive Bladder • Urinary Incontinence

Therapeutic outcomes and predictive factors of intradetrusor onabotulinumtoxinA for neurogenic detrusor overactivity (NDO) associated with spinal cord lesion. (PubMed, Int Urol Nephrol) - "Intradetrusor Botox produced good efficacy in SCL-related NDO. Higher baseline detrusor pressure, bladder contractility, and bladder outlet resistance predicted better outcomes, whereas greater VE was associated with nonresponse. Neurological level did not influence treatment success."

Biomarker • Journal

EXPRESS: Evaluation of Stress Biomarkers in individuals with Migraine or Tension-Type headached before and after Botulinum Toxin Injection. (PubMed, Mol Pain) - "The PREEMPT (Onabotulinum toxinS AntIpOde for chronic migraiNe) treatment protocol, a systematic procedure for treating chronic migraines, was administered to the patients. Biomarkers measured during the study were analyzed as surrogate measures of stress to shed light on potential physiological action of the intervention. Context In patients with chronic migraine and tension-type headaches, the effect of Nabota (Botulinum toxin type A) on specific stress-related indicators was evaluated.The results demonstrated a statistically significant (p<0.05) rise in salivary cortisol and a statistically significant (p<0.05) decrease in salivary alpha amylase following Botulinum toxin intervention for both research groups (chronic migraine, chronic tension headaches)."

Biomarker • Journal • CNS Disorders • Migraine • Pain

BC07 Patient-reported outcomes across repeat treatments for moderate-to-severe platysma prominence with onabotulinumtoxinA in a long-term, phase III, open-label extension study. (PubMed, Br J Dermatol) - "This research was funded by a commercial organization. No honoraria or payments were made for authorship."

Clinical • Journal • P3 data

Onabotulinumtoxin intra-detrusor injection for lower urinary tract symptoms (LUTS) in patients with multiple sclerosis (MS): A systematic review and meta-analysis. (PubMed, Caspian J Intern Med) - "The SMD of MCC (MCC week 4-MCC baseline) was 5.05 (95%CI: 0.14, 9.96) (I2=98.8%, p<0.001). This systematic review and meta-analysis demonstrated that injection of intra-detrusor Onabotulinumtoxin had a positive effect on improving urodynamic findings in patients with MS."

Journal • Retrospective data • Review • CNS Disorders • Infectious Disease • Multiple Sclerosis • Nephrology

Factors influencing the long-term maintenance of spasticity neurotoxin treatment. (PubMed, J Neurol Sci) - "Results suggest spasticity patients are likely to continue treatment if they are properly educated on BoNT therapy, experience improvement in spasms and mobility, and have a strong physician-patient relationship. These findings highlight the importance of effective physician-patient relationships and proper education on BoNT therapy."

Journal • Cardiovascular • Cerebral Palsy • CNS Disorders • Movement Disorders • Pain • Vascular Neurology

A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence (clinicaltrials.gov) - P3 | N=202 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion

Transversus abdominis release (TAR) versus preperitoneal repair (PPR) in complex, open abdominal wall reconstruction. (PubMed, Surgery) - "Compared with transversus abdominis release, preperitoneal abdominal wall reconstruction demonstrated equivalent hernia recurrence rates with fewer wound complications. Preperitoneal repair represents an effective approach to complex hernia repair for large defects, facilitating wide mesh placement while mitigating wound morbidity."

Journal • Anesthesia • Diabetes • Gastroenterology • Infectious Disease • Metabolic Disorders

A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants (clinicaltrials.gov) - P3 | N=249 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion

LET: Evaluation of Three Types of Injection for the Treatment of Lateral Epicondylalgia (clinicaltrials.gov) - P=N/A | N=13 | Terminated | Sponsor: Centre Hospitalier Universitaire de Nīmes | Completed ➔ Terminated; Discontinuation of production of the investigational medicinal product (PRP)

Trial termination • Musculoskeletal Pain

Botulinum Toxin for Refractory Vaginismus: A Therapeutic Evaluation of a Rare and Under-Researched Condition. (PubMed, JBRA Assist Reprod) - "This study highlights the high success rate of vaginal Botox treatment combined with psychological support, with 81.13% (86 out of 106 patients) achieving significant symptom relief and regaining pain-free intercourse. The treatment was well-tolerated and demonstrated substantial efficacy, reinforcing its potential as a viable intervention for vaginismus. However, 18.87% of patients did not experience symptom resolution, underscoring the complexity and heterogeneity of vaginismus. Notably, due to the rarity of this condition, this study represents one of the few conducted with such a large cohort, contributing valuable insights into the management of vaginismus. These findings emphasize the need for further research into individualized treatment strategies to optimize outcomes and address the varying needs of patients affected by this challenging and under-researched condition."

Journal • CNS Disorders • Pain • Sexual Disorders

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine (clinicaltrials.gov) - P3 | N=775 | Terminated | Sponsor: AbbVie | Completed ➔ Terminated; The study was terminated early due to lack of efficacy from the primary analysis results.

Trial termination • CNS Disorders • Migraine • Pain

Educational Gender Affirming Plastic Surgery Resident Injectables Clinic. (PubMed, Plast Reconstr Surg) - No abstract available

Journal • Aesthetic Medicine

BTX-A: Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection (clinicaltrials.gov) - P=N/A | N=20 | Not yet recruiting | Sponsor: Tishreen University

New trial

Reduction of surgical-site infections and improvement of scar parameters with a uniform fractional ultra-pulse CO₂ laser protocol in cosmetic surgery: a five-center retrospective cohort. (PubMed, Front Med (Lausanne)) - "A multicenter retrospective cohort enrolled 562 adults undergoing elective rhinoplasty, liposuction, breast augmentation, facelift, abdominoplasty, or Botox...All patients followed a five-day antibiotic regimen (oral cefalexin + topical mupirocin)...Standardized fractional ultra-pulse CO₂ laser therapy reduces SSIs, improves scar outcomes, and enhances patient satisfaction in cosmetic surgery. These findings support wider adoption of laser protocols, warranting further prospective, pathogen-specific research."

Journal • Retrospective data • Aesthetic Medicine • Cardiovascular • Fibrosis • Infectious Disease

Botulinum Toxin for the Treatment of Chronic Notalgia Paresthetica: A Case Report. (PubMed, Cureus) - "After experiencing persistent daily discomfort affecting her quality of life, she was treated with targeted intramuscular onabotulinumtoxinA (Botox) injections to the symptomatic area. The patient reported substantial improvement in symptoms following the second round of injections. This case highlights the potential role of botulinum toxin as an effective therapeutic option in managing refractory NP, particularly in patients who do not respond to standard therapies."

Journal • Dermatology • Pain • Pruritus

The Relax Study: investigation of adjuvant Botox injection in the surgical repair of complicated perianal fistula disease (ANZCTR) - P=N/A | N=20 | Not yet recruiting | Sponsor: Queen Elzabeth II Jubilee Hospital

New trial • Gastrointestinal Disorder

A retrospective audit of the real-world safety and effectiveness profile of eptinezumab for treatment-resistant chronic migraine in Australia. (PubMed, Headache) - "Our findings show that eptinezumab is a safe, well-tolerated migraine prophylactic that decreases monthly migraine and headache days in a small sample of Australian patients with treatment-resistant chronic migraine. Further prospective studies with larger sample sizes and longer follow-up data are needed to confirm findings of this study."

Journal • Real-world evidence • Retrospective data • CNS Disorders • Migraine • Pain

OnabotulinumtoxinA for Platysma Prominence: Safety and Efficacy Results from a Phase 3 Open-Label Repeat Treatment Study. (PubMed, Plast Reconstr Surg) - "Repeat onabotA treatment is well-tolerated and improves platysma prominence over the course of multiple treatment cycles."

Journal • P3 data • Gastrointestinal Disorder

Combination preventive therapy with onabotulinumtoxinA and atogepant for chronic migraine: A 24-week, prospective, real-world evaluation (SYNERGY study). (PubMed, Cephalalgia) - "Adverse events were mild and consistent with known safety profiles for both drugs separately; no novel safety concerns emerged.ConclusionsThe addition of atogepant to BoNTA might be effective and well tolerated in real-world setting, including CM patients previously exposed to multiple preventives. Prospective controlled trials and health-economic evaluations are warranted to validate these observations and inform future clinical guidelines."

HEOR • Journal • Real-world evidence • CNS Disorders • Migraine • Pain

MIGRA-MS: A case series on chronic migraine and multiple sclerosis (EHF-EHC 2025) - "Prior treatments included interferons and glatiramer acetate; current therapies consisted of ocrelizumab, natalizumab, alemtuzumab, teriflunomide, or dimethyl fumarate...All received a median of three classic preventives (amitriptyline in all cases) and onabotulinumtoxinA (PREEMPT, 155 IU) with only one responder; two patients received an extended dose (195 IU) without benefit and later CGRP monoclonal antibodies (galcanezumab, erenumab, eptinezumab) with no response, and atogepant with only transient or partial benefit...In this case series of relapsing–remitting MS with chronic resistant migraine, response to onabotulinumtoxinA and anti-CGRP therapies was limited, with no drug interactions or adverse effects observed. An individualized approach and further studies are needed to assess emerging treatments in this subgroup."

Clinical • CNS Disorders • Migraine • Multiple Sclerosis • Pain

Hypersensitivity Reactions Associated With Aesthetic Botulinum Toxin A Injections: A Case Series. (PubMed, Cureus) - "In the first case, a 44-year-old woman developed severe angioedema after resuming abobotulinumtoxinA injections following a 12-month pause. Subsequent intradermal tests with onabotulinumtoxinA and incobotulinumtoxinA produced localized reactions, suggesting hypersensitivity to a shared component across formulations, possibly the 150 kDa BoNT/A neurotoxin itself. In the second case, a 38-year-old woman experienced delayed erythema and swelling after letibotulinumtoxinA treatment but tolerated subsequent incobotulinumtoxinA injections, suggesting possible reactivity to complexing proteins or other non-core components rather than the neurotoxin. In the third case, a 50-year-old woman developed systemic symptoms and localized swelling after prabotulinumtoxinA administration, consistent with a delayed-type hypersensitivity reaction...Overall, this case series underscores the importance of clinical vigilance, appropriate patient selection, and awareness of rare but meaningful..."

Journal • Aesthetic Medicine • Cardiovascular • Dermatology • Immunology

External electrical stimulation with NERIVIO: Our experience in 3 cases of New Daily Persistent Headache (NDPH) (EHF-EHC 2025) - "Exhaustive work-up tests ruled out secondary causes and all of them were refractory to anesthetic block of Great Occipital Nerve and Sphenopalatine Ganglion, Onabotulinumtoxin A (PREEMPT protocol), anti-CGRP monoclonal antibody and more than five oral preventive drugs...The other 2 patients did not present any changes in their pain patern and intesity. NDPH is a frustrating disease refractory to all treatments including NERIVIO Stimulation in this small series."

Clinical • Anesthesia • CNS Disorders • Migraine • Pain